IP Library Granted Patent US 9,561,178
Granted Patent B2
US 9,561,178 · App. 11/781,095 · Granted Feb 7, 2017

Cyclosporin compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,561,178
App. No.
11/781,095
Granted
Feb 7, 2017
Kind
B2
Abstract

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.

Claims (10)

1. An aqueous solution comprising cyclosporin A at a concentration of about 0.0001% (w/v), Polysorbate 80, glycerin, mannitol, carboxymethylcellulose sodium, and water, wherein the aqueous solution contains no oil.

2. The solution of claim 1 , wherein the Polysorbate 80 is at a concentration of 1% (w/v), the glycerin is at a concentration of 1% (w/v), the mannitol is at a concentration of 0.5% (w/v), and the carboxymethylcellulose sodium is at a concentration of 0.5% (w/v).

3. The solution of claim 2 , further comprising sodium citrate dihydrate, potassium chloride, boric acid, and sodium borate decahydrate.

4. A method comprising topically administering a composition according to claim 1 to an eye of a mammal in need thereof to enhance or restore lacrimal gland tearing.

5. The method of claim 4 , wherein said method increases tear production in a tear-deficient eye.

6. The method of claim 4 , wherein said method is effective in treating keratoconjunctivitis sicca.

7. The method of claim 4 , wherein said method is effective in treating dry eye disease.

8. The method of claim 4 wherein the mammal is a human patient, and wherein less than 10% of human patients suffer burning or stinging when said composition is administered only once a day for a period of three months.

9. The method of claim 4 wherein the mammal is a human patient, and wherein less than 10% of human patients suffer ocular burning when said composition is administered only once a day for a period of three months.

10. The method of claim 4 wherein the composition is administered only once a day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: ALLERGAN, INC.
To: SAINT REGIS MOHAWK TRIBE
Reel/Frame 043830/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2008
From: TIEN, WALTER L.; ATTAR, MAYSSA; MORGAN, AILEEN; GRAHAM, RICHARD S.; SCHIFFMAN, RHETT
To: ALLERGAN, INC.
Reel/Frame 020547/0667 →